BioPorto Valuation
Is 2P4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2P4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2P4's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2P4's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2P4?
Key metric: As 2P4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2P4's PS Ratio? | |
|---|---|
| PS Ratio | 20.6x |
| Sales | DKK 33.83m |
| Market Cap | DKK 696.90m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.7x |
| Enterprise Value/EBITDA | -11.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2P4's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.3x | ||
HPHA Heidelberg Pharma | 12.5x | 16.6% | €106.3m |
2INV 2invest | 7.7x | n/a | €59.8m |
MDG1 Medigene | 3.3x | 16.1% | €24.3m |
FYB Formycon | 13.5x | 32.5% | €820.2m |
2P4 BioPorto | 20.6x | 29.2% | €696.9m |
Price-To-Sales vs Peers: 2P4 is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (9.3x).
Price to Sales Ratio vs Industry
How does 2P4's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 2P4 is expensive based on its Price-To-Sales Ratio (20.6x) compared to the European Biotechs industry average (7.8x).
Price to Sales Ratio vs Fair Ratio
What is 2P4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 20.6x |
| Fair PS Ratio | 3.6x |
Price-To-Sales vs Fair Ratio: 2P4 is expensive based on its Price-To-Sales Ratio (20.6x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.29
7D
3.1%
1Y
-7.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-2.6%
1Y
86.3%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.35
7D
-4.5%
1Y
-2.3%